Rusfertide decreased phlebotomy want and improved high quality of life in sufferers with polycythemia vera, based on part 3 VERIFY trial outcomes.
Remedy with the investigational therapeutic rusfertide has confirmed to be a possible remedy possibility for sufferers with polycythemia vera, a sort of blood most cancers, primarily based on latest information from the part 3 VERIFY trial, which have been shared on the 2025 ASCO Annual Assembly.
Rusfertide has been proven to cut back or eradicate the necessity for phlebotomies, a process which removes additional blood cells from the physique by utilizing a needle to take blood from the vein, thus enhancing high quality of life and enhancing symptom management, based on Dr. Aaron Gerds.
“[Rusfertide] is a brand new remedy that’s assuaging the necessity for phlebotomies and enhancing sufferers’ high quality of life. That is extremely necessary for sufferers. Having one other instrument in our arsenal to take care of these sufferers is actually thrilling,” Gerds defined in an interview with CURE.
Within the interview, he highlighted what sufferers with polycythemia vera ought to know concerning the VERIFY trial, the importance of having the ability to forgo normal phlebotomy with rusfertide, and the way people can entry rising therapies like this one.
Gerds is an assistant professor within the Division of Drugs on the Case Complete Most cancers Heart College of Drugs, the place he’s additionally a member of the Developmental Therapeutics Program. He additionally serves as a doctor within the Division of Hematology and Medical Oncology on the Cleveland Clinic, positioned in Ohio.
CURE: What ought to sufferers know concerning the VERIFY trial, offered at this 12 months’s ASCO Annual Assembly?
The ASCO Annual Assembly is at all times a difficult convention for these of us in hematology. Hematologic neoplasms usually symbolize a smaller portion of the bigger ASCO assembly, and generally you actually need to sift via quite a few abstracts to seek out one thing actually spectacular. Nevertheless, this 12 months, we had the lucky occasion of a hematologic malignancy being featured as a plenary summary. That is the celebrated session the place they choose the highest few abstracts to current to an enormous, huge crowd, genuinely highlighting the significance of this analysis.
The truth that it issues polycythemia vera is especially important for a considerably uncommon blood most cancers that usually would not obtain a lot consideration. It is a illness we have identified a fantastic deal about for a very long time however have comparatively few authorized therapies. As of at the moment, there are solely two FDA-approved medication for polycythemia vera: Rituxan, authorized within the second-line setting, and Besremi (ropeginterferon alfa-2b-njft), authorized for all settings. Given this restricted therapeutic panorama, a brand new, efficient drug like rusfertide, which presents a very totally different mechanism, is totally warranted for the sphere.
Are you able to stroll us via the importance of the medical trials evaluating rusfertide in polycythemia vera?
The trial offered at this 12 months’s ASCO assembly was a basic, definitive part 3 registration research. It included sufferers who acquired the drug and those that didn’t, permitting for an intensive comparability with all of the statistical energy wanted for regulatory approval. This was the trial in query.
This pivotal research was preceded by a part 2 trial that convincingly confirmed that administering rusfertide may eradicate the necessity for phlebotomies. Within the part 2 trial, there was a blinded, randomized interval the place sufferers might or might not have acquired the drug. As soon as unblinded, it was clear that when the drug was used, the necessity for phlebotomy disappeared. When the drug was withdrawn, the necessity for phlebotomies returned, and as soon as the drug was re-administered, the necessity for phlebotomies once more resolved. This actually proved the mechanism of motion in a real-world setting, which was important for shifting ahead with the part 3 trial.
Within the part 3 research, once more, it was a randomized, potential trial the place some sufferers acquired rusfertide and others didn’t. The highest-line outcomes indicated that between weeks 20 and 32 of the trial, 77% of sufferers taking rusfertide had a medical response, in contrast with 33% within the management group. Scientific response, on this context, primarily refers back to the management of blood counts, as that is the principle issue we monitor in polycythemia vera: can we hold the hematocrit below 45%?
What I discover actually attention-grabbing are a few of the extra information offered. Sufferers’ high quality of life and symptom burden have been higher on rusfertide in comparison with the management group, which is necessary. Whereas eliminating the necessity for phlebotomies is nice, the power to do one thing extra — to genuinely enhance sufferers’ lives — is a big development.
What will we presently learn about how rusfertide impacts signs like fatigue or focus? Is there any proof rusfertide improves high quality of life in contrast with normal phlebotomy?
We definitely noticed within the part 2 trial that sufferers on rusfertide skilled a greater high quality of life on remedy in comparison with earlier than they began. That was our first clue. Within the ASCO presentation, we additionally noticed enhancements in signs and general high quality of life. Moreover, when evaluating sufferers on rusfertide to these within the management group, we noticed extra enhancements. This implies there’s not solely intra-patient enchancment (people feeling higher whereas on the drug) but additionally inter-patient enchancment (these receiving the remedy feeling higher than those that didn’t). I believe this twin perspective is extremely necessary.
Why do individuals really feel higher? That is one other wonderful query. A part of the reason being largely on account of iron deficiency. We regularly deal with polycythemia vera utilizing phlebotomies, which result in iron deficiency. That is how phlebotomies management crimson blood cell manufacturing. Nevertheless, iron deficiency itself may cause many signs, akin to fatigue, muscle, and joint aches and pains. There’s additionally a really well-known symptom known as pica, the place you might have an urge to eat ice or filth. So, many signs can accompany the iron deficiency induced by phlebotomies, which is the normal mechanism for treating polycythemia vera.
Rusfertide works in a different way. It is a artificial model that mimics hepcidin, our physique’s pure regulator of iron. Consider hepcidin like a cork in a bottle. If the “bottle” represents your iron shops, hepcidin successfully “corks” the opening, stopping iron from leaving. So, you’ll be able to put iron into the shops, however rusfertide will not let it out. On this method, iron stays in storage, but the bone marrow “thinks” it is iron-deficient and may’t produce crimson blood cells because it usually would. It is basically tricking the bone marrow into believing it is iron-deficient even when your physique is not. This enables for the management of crimson blood cell counts with out essentially experiencing all of the signs related to iron deficiency, which I discover to be a intelligent strategy.
We have identified about hepcidin for a very long time; it is one thing we realized about in medical faculty. This information has been round for some time, however that is actually the primary time we’re harnessing its energy on this particular strategy to deal with polycythemia vera. Taking a step again, one even cooler a part of this entire story is that we’re really focusing on hepcidin in the wrong way for one more situation. We’re attempting to decrease hepcidin ranges in myelofibrosis and related anemia.
Myelofibrosis is a carefully associated illness to polycythemia vera, a part of the identical household of ailments attributable to related mutations, however we frequently see anemia in these sufferers. So, in myelofibrosis-associated anemia, we’re attempting to decrease hepcidin ranges to enhance, or improve, crimson blood cell counts. In polycythemia vera, we’re doing the other: we’re attempting to lift hepcidin ranges, or successfully elevate them, to decrease crimson blood cell counts. Thus, throughout the identical discipline and successfully the identical illness household, we’re manipulating this pathway in two other ways to realize two distinct results.
If a affected person’s hematocrit is already well-managed with phlebotomy, would they nonetheless profit from rusfertide, or is that this remedy higher fitted to these with extra difficult-to-control illness?
Each the part 2 and part 3 trials inform us that it is efficient for each teams. Sufferers who’re solely getting phlebotomies present all these advantages. Moreover, for sufferers who’re on hydroxyurea, Rituxan, or an interferon however nonetheless require phlebotomies, including rusfertide on high of their present remedy can enhance each their blood depend management and their signs and high quality of life. So, I believe in each conditions, it may be useful.
What elements will decide whether or not rusfertide turns into a extensively accessible possibility for sufferers, and the way can people advocate for entry to rising therapies like this one?
That can definitely take extra time. These are simply the preliminary, top-line outcomes — the week 32 information. The week 52 information is anticipated across the spring of 2026, so you’ll be able to mark that in your calendars. I consider the longer-term information will likely be useful in answering these questions.
The corporate that makes the drug is definitely in conversations with regulatory authorities, asking, “What else is required to have a very good likelihood of approval to submit that new drug software?” That is going to be the following step: gathering all the info, your entire packet, and placing collectively a brand new drug software to undergo the regulatory authorities, or the U.S. Meals and Drug Administration (FDA) on this case. Then, that packet or software, if you’ll, will get reviewed by the FDA. There’s numerous critiques, hearings, and every kind of processes that associate with that. On the again finish of that, that is once we’ll have a choice on regulatory approval.
Regulatory approval is simply that subsequent step. If you say, “entry and extensively obtainable,” the step after that’s insurance coverage protection. Right here in the USA, our healthcare system is usually run by insurance coverage firms. What is going to that regulatory approval seem like? What is going to it embody? What ranges of illness and what parameters? Then there will likely be tips that come out, for instance, from the NCCN, which is able to make guideline suggestions on the usage of rusfertide. These two elements will likely be taken collectively, together with pricing and different elements. Then the insurance coverage firms will resolve what they are going to and will not cowl, and that will really affect entry for lots of sufferers.
What would you want sufferers to remove from at the moment’s dialog?
There are a few actually necessary issues to think about. First, we’re constantly creating new therapies for polycythemia vera. Though it is a uncommon illness and sometimes not highlighted within the grand pantheon of ailments offered at ASCO, it stays an important situation, particularly for the sufferers who reside with it. A devoted group of us may be very on this illness and dealing arduous to develop new therapies. It isn’t simply rusfertide in improvement; there are different medication focusing on the hepcidin pathway, in addition to medication outdoors that pathway. For example, givinostat is in a randomized part 3 registration-type research, additionally in search of approval. So, regardless that it is a uncommon illness, important effort is being put into creating new and higher therapies for our sufferers. I consider that is essentially the most essential take-home level.
Concerning rusfertide particularly, I believe it is thrilling. It is a new remedy that’s assuaging the necessity for phlebotomies and enhancing sufferers’ high quality of life. That is extremely necessary for sufferers. Having one other instrument in our arsenal to take care of these sufferers is actually thrilling and, I consider, can provide loads for these dwelling with polycythemia vera.
Transcript has been edited for readability and conciseness.
For extra information on most cancers updates, analysis and schooling, don’t neglect to subscribe to CURE®’s newsletters right here.
